10.28
1.08%
+0.11
After Hours:
10.00
-0.28
-2.72%
Amicus Therapeutics Inc stock is currently priced at $10.28, with a 24-hour trading volume of 1.70M.
It has seen a +1.08% increased in the last 24 hours and a -10.06% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $10.22 pivot point. If it approaches the $10.42 resistance level, significant changes may occur.
Previous Close:
$10.17
Open:
$10.26
24h Volume:
1.70M
Market Cap:
$3.04B
Revenue:
$399.36M
Net Income/Loss:
$-151.58M
P/E Ratio:
-16.06
EPS:
-0.64
Net Cash Flow:
$-76.53M
1W Performance:
-3.11%
1M Performance:
-10.06%
6M Performance:
-5.34%
1Y Performance:
-11.07%
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Name
Amicus Therapeutics Inc
Sector
Industry
Phone
609-662-2000
Address
1 Cedar Brook Drive, Cranbury, NJ
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
Apr-13-22 | Resumed | Goldman | Neutral |
Jan-14-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Nov-15-21 | Upgrade | Stifel | Hold → Buy |
Sep-30-21 | Upgrade | JP Morgan | Neutral → Overweight |
Jul-19-21 | Resumed | BTIG Research | Buy |
May-27-21 | Initiated | Needham | Hold |
May-21-21 | Initiated | UBS | Buy |
Apr-14-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Mar-02-21 | Initiated | Stifel | Hold |
Feb-12-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
Dec-28-20 | Resumed | Cantor Fitzgerald | Overweight |
Dec-10-20 | Downgrade | Citigroup | Buy → Neutral |
Nov-11-20 | Initiated | Berenberg | Hold |
Jun-17-20 | Initiated | BTIG Research | Buy |
Feb-04-20 | Resumed | Cantor Fitzgerald | Overweight |
Nov-12-19 | Reiterated | H.C. Wainwright | Buy |
Jun-17-19 | Initiated | H.C. Wainwright | Buy |
Jun-05-19 | Reiterated | Cantor Fitzgerald | Overweight |
Apr-05-19 | Initiated | Janney | Buy |
Jan-30-19 | Initiated | Cantor Fitzgerald | Overweight |
Oct-29-18 | Initiated | Citigroup | Neutral |
Aug-17-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Oct-06-17 | Resumed | Goldman | Neutral |
Sep-13-17 | Reiterated | Chardan Capital Markets | Buy |
Aug-10-17 | Reiterated | Chardan Capital Markets | Buy |
Jan-24-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
May-18-16 | Initiated | BofA/Merrill | Buy |
Apr-14-16 | Initiated | Robert W. Baird | Neutral |
Apr-12-16 | Reiterated | Chardan Capital Markets | Buy |
Sep-16-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Jun-16-15 | Reiterated | Chardan Capital Markets | Buy |
View All
Amicus Therapeutics Inc Stock (FOLD) Latest News
Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report?
Zacks Investment Research
Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates
Zacks Investment Research
Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
GlobeNewswire Inc.
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
GlobeNewswire Inc.
Time to Buy These 3 Healthcare Companies That Raised Revenue Guidance?
Investing.com
Amicus Therapeutics Inc Stock (FOLD) Financials Data
Amicus Therapeutics Inc (FOLD) Revenue 2024
FOLD reported a revenue (TTM) of $399.36 million for the quarter ending December 31, 2023, a +21.30% rise year-over-year.
Amicus Therapeutics Inc (FOLD) Net Income 2024
FOLD net income (TTM) was -$151.58 million for the quarter ending December 31, 2023, a +35.92% increase year-over-year.
Amicus Therapeutics Inc (FOLD) Cash Flow 2024
FOLD recorded a free cash flow (TTM) of -$76.53 million for the quarter ending December 31, 2023, a +55.07% increase year-over-year.
Amicus Therapeutics Inc (FOLD) Earnings per Share 2024
FOLD earnings per share (TTM) was -$0.51 for the quarter ending December 31, 2023, a +37.80% growth year-over-year.
About Amicus Therapeutics Inc
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease. The company has a strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease, as well as a research and development collaboration with the University of Pennsylvania to develop AAV gene therapies. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Cap:
|
Volume (24h):